PARP1 and central nervous system cancer: Interestingly, the drug targets identified in this study include PARP1, for which there is an active phase II clinical trial testing PARP-inhibitor Veliparib (ABT-888) in combination with radiotherapy and temzolomiode for H3 WT high-grade glioma (NCT03581292).